Photo of Michael Hartman

Clients trust Michael with a wide range of complex litigation and investigation matters, including class actions, antitrust and competition disputes, and white collar cases.

Over the past several years, the Democratic commissioners of the U.S. Federal Trade Commission (FTC) have made clear their dissatisfaction with the agency’s historic treatment of pharmaceutical mergers. Now, it appears that the FTC has launched a process aimed at changing the way in which such transactions are analyzed and ultimately resolved.

Past dissenting statements